284 related articles for article (PubMed ID: 11578915)
1. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL).
Weiden PL; Breitz HB
Crit Rev Oncol Hematol; 2001 Oct; 40(1):37-51. PubMed ID: 11578915
[TBL] [Abstract][Full Text] [Related]
2. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
Weiden PL; Breitz HB; Press O; Appelbaum JW; Bryan JK; Gaffigan S; Stone D; Axworthy D; Fisher D; Reno J
Cancer Biother Radiopharm; 2000 Feb; 15(1):15-29. PubMed ID: 10740649
[TBL] [Abstract][Full Text] [Related]
3. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
Breitz HB; Fisher DR; Goris ML; Knox S; Ratliff B; Murtha AD; Weiden PL
Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
[TBL] [Abstract][Full Text] [Related]
4. Pretargeted radioimmunotherapy (PRIT) using an antibody-streptavidin fusion protein in non-Hodgkin's lymphoma.
Weiden PL
Leuk Lymphoma; 2002 Oct; 43(10):1971-3. PubMed ID: 12481894
[TBL] [Abstract][Full Text] [Related]
5. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin.
Breitz HB; Weiden PL; Beaumier PL; Axworthy DB; Seiler C; Su FM; Graves S; Bryan K; Reno JM
J Nucl Med; 2000 Jan; 41(1):131-40. PubMed ID: 10647616
[TBL] [Abstract][Full Text] [Related]
6. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.
Pagel JM; Lin Y; Hedin N; Pantelias A; Axworthy D; Stone D; Hamlin DK; Wilbur DS; Press OW
Blood; 2006 Jul; 108(1):328-36. PubMed ID: 16556891
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
[TBL] [Abstract][Full Text] [Related]
10. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.
Pagel JM; Hedin N; Subbiah K; Meyer D; Mallet R; Axworthy D; Theodore LJ; Wilbur DS; Matthews DC; Press OW
Blood; 2003 Mar; 101(6):2340-8. PubMed ID: 12446461
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Wiseman GA; White CA; Sparks RB; Erwin WD; Podoloff DA; Lamonica D; Bartlett NL; Parker JA; Dunn WL; Spies SM; Belanger R; Witzig TE; Leigh BR
Crit Rev Oncol Hematol; 2001; 39(1-2):181-94. PubMed ID: 11418315
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Forero A; Weiden PL; Vose JM; Knox SJ; LoBuglio AF; Hankins J; Goris ML; Picozzi VJ; Axworthy DB; Breitz HB; Sims RB; Ghalie RG; Shen S; Meredith RF
Blood; 2004 Jul; 104(1):227-36. PubMed ID: 14996706
[TBL] [Abstract][Full Text] [Related]
14. Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.
Forero-Torres A; Shen S; Breitz H; Sims RB; Axworthy DB; Khazaeli MB; Chen KH; Percent I; Besh S; LoBuglio AF; Meredith RF
Cancer Biother Radiopharm; 2005 Aug; 20(4):379-90. PubMed ID: 16114986
[TBL] [Abstract][Full Text] [Related]
15. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Marcus R
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
[TBL] [Abstract][Full Text] [Related]
16. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.
Pagel JM; Matthews DC; Kenoyer A; Hamlin DK; Wilbur DS; Fisher DR; Gopal AK; Lin Y; Saganic L; Appelbaum FR; Press OW
Cancer Res; 2009 Jan; 69(1):185-92. PubMed ID: 19118002
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.
Chinn PC; Leonard JE; Rosenberg J; Hanna N; Anderson DR
Int J Oncol; 1999 Nov; 15(5):1017-25. PubMed ID: 10536187
[TBL] [Abstract][Full Text] [Related]
18. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma.
Witzig TE
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S91-5. PubMed ID: 11587375
[TBL] [Abstract][Full Text] [Related]
20. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.
Park SI; Shenoi J; Pagel JM; Hamlin DK; Wilbur DS; Orgun N; Kenoyer AL; Frayo S; Axtman A; Bäck T; Lin Y; Fisher DR; Gopal AK; Green DJ; Press OW
Blood; 2010 Nov; 116(20):4231-9. PubMed ID: 20702781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
